LEADER 04112nam  22005295  450 
001 9910739446603321
005 20251116191238.0
010   $a3-319-60570-4
024 7 $a10.1007/978-3-319-60570-8
035   $a(CKB)4100000000587380
035   $a(DE-He213)978-3-319-60570-8
035   $a(MiAaPQ)EBC5017535
035   $a(PPN)204536332
035   $a(EXLCZ)994100000000587380
100   $a20170901d2018      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 14$aThe Bethesda System for Reporting Thyroid Cytopathology $eDefinitions, Criteria, and Explanatory Notes /$fedited by Syed Z. Ali, Edmund S. Cibas
205   $a2nd ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (XV, 236 p. 224 illus. in color.) 
311 08$a3-319-60569-0 
320   $aIncludes bibliographical references and index.
327   $aOverview of Diagnostic Terminology and Reporting -- Nondiagnostic/Unsatisfactory -- Benign -- Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance -- Follicular Neoplasm/Suspicious for a Follicular Neoplasm -- Follicular Neoplasm, Hürthle Cell (Oncocytic) Type/Suspicious for a Follicular Neoplasm, Hürthle Cell (Oncocytic) Type -- Suspicious for Malignancy -- Papillary Thyroid Carcinoma, Variants, and Related Tumors -- Medullary Thyroid Carcinoma -- Poorly Differentiated Thyroid Carcinoma -- Undifferentiated (Anaplastic) Carcinoma and Squamous Cell Carcinoma of the Thyroid -- Metastatic Tumors, Lymphomas, and Rare Tumors of the Thyroid.
330   $a The first edition of The Bethesda System for Reporting Thyroid Cytopathology was published in 2010 and has greatly influenced the practice of thyroid cytopathology. The terminology proposed and illustrated in this text has been widely adopted not only in the U.S. but also abroad. It has become an essential text for pathology trainees and practicing pathologists examining thyroid fine needle aspiration (FNA) specimens. Since 2010, there have been a number of important advances in the management of patients with nodular thyroid disease and in the understanding of the biology of thyroid cancer. This new edition includes these advances that impact terminology for reporting thyroid cytopathology. In particular, it incorporates a discussion of the recently implemented and now widespread use of molecular testing of thyroid FNA samples, which has transformed the management of patients with nodular thyroid disease in the U.S.. In addition, this edition accommodates the recent changes to the classification of thyroid cancer, most notably the introduction of a new thyroid diagnosis, that of "non-invasive follicular tumor with papillary-like nuclear features (NIFTP)". Thoroughly revised and updated, The Bethesda System for Reporting Thyroid Cytopathology, Second Edition will provide the reader with a unified approach to diagnosing and reporting thyroid FNA interpretations. It serves as a reference guide not just for pathologists, but also endocrinologists, surgeons, and radiologists.
606   $aPathology
606   $aEndocrinology
606   $aCancer$xSurgery
606   $aPathology$3https://scigraph.springernature.com/ontologies/product-market-codes/H4800X
606   $aEndocrinology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33053
606   $aSurgical Oncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H59150
615  0$aPathology.
615  0$aEndocrinology.
615  0$aCancer$xSurgery.
615 14$aPathology.
615 24$aEndocrinology.
615 24$aSurgical Oncology.
676   $a616.07
702   $aAli$b Syed Z.$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aCibas$b Edmund S.$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910739446603321
996   $aThe Bethesda System for Reporting Thyroid Cytopathology$93553861
997   $aUNINA